Road to IBD Prevention in the Global South: A Conceptual Framework Modeling From Non-Communicabl

07 Apr 20264 min read0 viewsJournal Feed

GIST

IBD is rising worldwide and is now a global disease. With the expanding armamentarium of medical therapies, including biologics and small molecules, there is a decline in hospitalisation rates and IBD-related surgeries.

However, high costs, injectable therapy, risk of opportunistic infections and the lifelong nature of the disease pose significant challenges in the management of IBD. Developing countries are also constrained by a lack of trained manpower, as well as economic and infrastructural limitations.

Strategies aimed at the prevention of IBD may alleviate the suffering and cost of this disease. Suggested approaches include implementation of prevention and interception trials using dietary, pharmacological and precision medicine approaches.

However, these would necessitate massive funding and equitable infrastructural support for identifying the population at risk (for prevention trials) and those with preclinical disease (for interception trials). Hence, these strategies are unlikely to be globally practicable or economically viable, particularly in the Global South.

It is believed that IBD, like certain non-communicable diseases (NCDs) such as metabolic syndrome and cardiovascular disorders, may be preventable by modifying the risk factors.

Clinical Editorial

Summary

A Global Perspective on IBD Prevention: Framing a Viable Pathway for the Global South

Context and Diagnostic Horizon

The piece situates inflammatory bowel disease (IBD) as a rising, global health issue, with expanding therapeutic options including biologics and small molecules.
Despite therapeutic advances, hospitalizations and IBD-related surgeries have declined in some settings, yet challenges persist due to high costs, injectable treatment formats, opportunistic infection risk, and the lifelong nature of disease management.

Limitations and Resource Constraints in the Global South

The authors highlight constraints in developing countries, notably shortages of trained personnel and broader economic and infrastructural limitations.
These realities influence the feasibility of prevention and interception trials for IBD, which would require large-scale funding and robust infrastructure to identify at-risk populations and those with preclinical disease.

Proposed Strategic Shift: From Trials to Practical Prevention Frameworks

Given feasibility concerns, the article advocates for an alternative approach that leverages existing, time-tested non-communicable disease (NCD) prevention strategies.
The central thesis is to blend evidence-based IBD prevention concepts with established NCD prevention practices rather than pursuing resource-intensive, large-scale prevention/interception trials.

Mechanism for Selecting Preventive Measures

This entails identifying measures that (1) have evidence supporting a preventive effect on IBD, (2) are aligned with NCD prevention paradigms, and (3) are economically viable.

The authors propose a sieving framework to curate preventive interventions.
The emphasis is on practical relevance and cost considerations to maximize applicability in resource-limited settings.

Evidence Context and Practical Relevance

The review reframes IBD prevention by drawing parallels with NCD prevention models, aiming for measures that can be implemented within the constraints of Global South health systems.